Arcturus Therapeutics Holdings Inc
$ 7.58
-4.17%
04 Mar - close price
- Market Cap 215,380,000 USD
- Current Price $ 7.58
- High / Low $ 7.70 / 6.79
- Stock P/E N/A
- Book Value 8.24
- EPS -2.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.27 %
- 52 Week High 24.17
- 52 Week Low 5.85
About
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
Analyst Target Price
$27.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-10 | 2025-08-04 | 2025-06-13 | 2025-03-05 | 2024-11-07 | 2024-08-05 | 2024-05-08 | 2024-03-07 | 2023-11-14 | 2023-08-07 | 2023-05-09 |
| Reported EPS | -1.03 | -0.49 | -0.34 | -0.52 | -1.11 | -0.26 | -0.64 | -1 | -0.32 | -0.61 | -1.98 | 1.87 |
| Estimated EPS | 4.28 | 5.53 | 3.21 | -1.19 | -0.4943 | -1.22 | -1.6 | -1.19 | -0.99 | -1.69 | -0.21 | 0.06 |
| Surprise | -5.31 | -6.02 | -3.55 | 0.67 | -0.6157 | 0.96 | 0.96 | 0.19 | 0.67 | 1.08 | -1.77 | 1.81 |
| Surprise Percentage | -124.0654% | -108.8608% | -110.5919% | 56.3025% | -124.56% | 78.6885% | 60% | 15.9664% | 67.6768% | 63.9053% | -842.8571% | 3016.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARCT
2026-03-03 21:51:53
Arcturus Therapeutics Holdings Inc. reported a significant decline in fourth-quarter revenue, down 68% year-over-year to $7.2 million, primarily due to reduced collaboration revenue from CSL. Despite this, the company's net loss improved slightly, and it reduced operating expenses. Arcturus also highlighted progress in its rare disease therapeutic portfolio and extended its cash runway into the second quarter of 2028.
2026-03-03 21:51:53
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported first-quarter EPS of $-1.03, significantly missing analyst estimates of $4.28 by $5.31. The company's revenue also fell short, coming in at $7.2 million compared to the consensus estimate of $232.52 million. Despite the earnings miss, Arcturus Therapeutics' stock has shown a 10.94% increase in the last three months, though it is down -48.93% over the past year.
2026-03-03 20:51:53
Arcturus Therapeutics reported its financial results for Q4 and fiscal year 2025, highlighting a decrease in revenue and operating expenses compared to 2024. The company announced pipeline advancements, including plans to initiate a 12-week Phase 2 study for ARCT-032 in cystic fibrosis in H1 2026 and an expanded development strategy for ARCT-810 in OTC deficiency. Arcturus also noted an extended cash runway into Q2 2028 and ongoing legal proceedings.
2026-03-02 15:52:42
This article analyzes Arcturus Therapeutics Holdings Inc. (ARCT) using AI models to provide trading strategies. It highlights a mid-channel oscillation pattern and presents institutional strategies for long and short positions, along with multi-timeframe signal analysis indicating strong near-to-mid-term sentiment but a weak long-term outlook. The analysis also notes an exceptional risk-reward short setup with significant downside potential.
2026-02-27 21:51:56
Arcturus Therapeutics Holdings Inc (ARCT) is anticipated to report a loss of 71 cents per share in its upcoming earnings. This forecast is based on information provided by Refinitiv and Reuters. The article serves as an earnings preview for investors following the company.
2026-02-21 10:47:07
Arcturus Therapeutics announced its financial results for Q2 2024, reporting a significant revenue increase to $49.9 million, up from $10.5 million in Q2 2023, and a narrowed net loss. The company highlighted progress in its clinical pipeline, including an IND submission for ARCT-032 in cystic fibrosis, anticipated Q4 2024 data for ARCT-810, and the upcoming commercial launch of Kostaive® in Japan. Arcturus expects its cash runway to extend through Q1 2027, supporting ongoing development.
